171 related articles for article (PubMed ID: 37634210)
21. SMARCA2 deficiency in NSCLC: a clinicopathologic and immunohistochemical analysis of a large series from a single institution.
Sun S; Li Q; Zhang Z; Xiong S; Zhang Y; Liu Q; Li Z; Yang F; Zhang S
Environ Health Prev Med; 2022; 27():3. PubMed ID: 35289322
[TBL] [Abstract][Full Text] [Related]
22. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features.
Kinoshita F; Kohashi K; Sugimoto M; Takamatsu D; Kiyozawa D; Eto M; Oda Y
Virchows Arch; 2020 Nov; 477(5):651-660. PubMed ID: 32447490
[TBL] [Abstract][Full Text] [Related]
23. Ovarian high-grade serous carcinoma cells with low SMARCA4 expression and high SMARCA2 expression contribute to platinum resistance.
Kido K; Nojima S; Motooka D; Nomura Y; Kohara M; Sato K; Ohshima K; Tahara S; Kurashige M; Umeda D; Takashima T; Kiyokawa H; Ukon K; Matsui T; Okuzaki D; Morii E
J Pathol; 2023 May; 260(1):56-70. PubMed ID: 36763038
[TBL] [Abstract][Full Text] [Related]
24. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
25. Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.
Reichl KD; Lee ECY; Gopalsamy A
Expert Opin Ther Pat; 2024 Mar; 34(3):159-169. PubMed ID: 38578210
[TBL] [Abstract][Full Text] [Related]
26. SMARCA4/SMARCA2-deficient Carcinoma of the Esophagus and Gastroesophageal Junction.
Horton RK; Ahadi M; Gill AJ; Said S; Chen ZE; Bakhshwin A; Nichols M; Goldblum JR; Graham RP
Am J Surg Pathol; 2021 Mar; 45(3):414-420. PubMed ID: 33027072
[TBL] [Abstract][Full Text] [Related]
27. Analysis of SMARCA4 and SMARCA2 Loss in Lung Sarcomatoid Carcinomas.
Urer HN; Unver N; Fener N
Turk Patoloji Derg; 2023; 39(2):147-153. PubMed ID: 36178285
[TBL] [Abstract][Full Text] [Related]
28. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
29. Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas.
Karnezis AN; Hoang LN; Coatham M; Ravn S; Almadani N; Tessier-Cloutier B; Irving J; Meng B; Li X; Chow C; McAlpine J; Kuo KT; Mao TL; Djordjevic B; Soslow RA; Huntsman DG; Blake Gilks C; Köbel M; Lee CH
Mod Pathol; 2016 Mar; 29(3):302-14. PubMed ID: 26743474
[TBL] [Abstract][Full Text] [Related]
30. Heterozygous Mutations in SMARCA2 Reprogram the Enhancer Landscape by Global Retargeting of SMARCA4.
Gao F; Elliott NJ; Ho J; Sharp A; Shokhirev MN; Hargreaves DC
Mol Cell; 2019 Sep; 75(5):891-904.e7. PubMed ID: 31375262
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of SWI/SNF Protein Expression by Immunohistochemistry in Ovarian Clear Cell Carcinoma.
Bennett JA; Safdar N; Segal JP; Lastra RR; Oliva E
Int J Gynecol Pathol; 2021 Mar; 40(2):156-164. PubMed ID: 32897960
[TBL] [Abstract][Full Text] [Related]
32. Tumor progression by epithelial-mesenchymal transition in ARID1A- and SMARCA4-aberrant solid-type poorly differentiated gastric adenocarcinoma.
Sasaki T; Kohashi K; Kawatoko S; Ihara E; Oki E; Nakamura M; Ogawa Y; Oda Y
Virchows Arch; 2022 May; 480(5):1063-1075. PubMed ID: 34997313
[TBL] [Abstract][Full Text] [Related]
33. SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1/ERBB2 co-amplification.
Pries K; Krüger S; Heckl S; Behrens HM; Röcken C
Cancer Med; 2023 May; 12(9):10423-10437. PubMed ID: 36916408
[TBL] [Abstract][Full Text] [Related]
34. Relationship between cellular morphology and abnormality of SWI/SNF complex subunits in pancreatic undifferentiated carcinoma.
Yamamoto T; Kohashi K; Yamada Y; Kawata J; Sakihama K; Matsuda R; Koga Y; Aishima S; Nakamura M; Oda Y
J Cancer Res Clin Oncol; 2022 Nov; 148(11):2945-2957. PubMed ID: 34817661
[TBL] [Abstract][Full Text] [Related]
35. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Cantley J; Ye X; Rousseau E; Januario T; Hamman BD; Rose CM; Cheung TK; Hinkle T; Soto L; Quinn C; Harbin A; Bortolon E; Chen X; Haskell R; Lin E; Yu SF; Del Rosario G; Chan E; Dunlap D; Koeppen H; Martin S; Merchant M; Grimmer M; Broccatelli F; Wang J; Pizzano J; Dragovich PS; Berlin M; Yauch RL
Nat Commun; 2022 Nov; 13(1):6814. PubMed ID: 36357397
[TBL] [Abstract][Full Text] [Related]
36. Infrequent loss of SMARCA4, SMARCA2, and SMARCB1 expression in uterine mesenchymal tumors.
Kihara A; Amano Y; Matsubara D; Fukushima N; Fujiwara H; Niki T
Hum Pathol; 2021 Oct; 116():12-21. PubMed ID: 34271067
[TBL] [Abstract][Full Text] [Related]
37. A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers.
Peng L; Li J; Wu J; Xu B; Wang Z; Giamas G; Stebbing J; Yu Z
Front Immunol; 2021; 12():762598. PubMed ID: 34675941
[TBL] [Abstract][Full Text] [Related]
38. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
[TBL] [Abstract][Full Text] [Related]
39. SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca
Xue Y; Morris JL; Yang K; Fu Z; Zhu X; Johnson F; Meehan B; Witkowski L; Yasmeen A; Golenar T; Coatham M; Morin G; Monast A; Pilon V; Fiset PO; Jung S; Gonzalez AV; Camilleri-Broet S; Fu L; Postovit LM; Spicer J; Gotlieb WH; Guiot MC; Rak J; Park M; Lockwood W; Foulkes WD; Prudent J; Huang S
Nat Commun; 2021 Sep; 12(1):5404. PubMed ID: 34518526
[TBL] [Abstract][Full Text] [Related]
40. SMARCA4: Current status and future perspectives in non-small-cell lung cancer.
Tian Y; Xu L; Li X; Li H; Zhao M
Cancer Lett; 2023 Feb; 554():216022. PubMed ID: 36450331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
